Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its Oncology Pipeline

Shots:

• AZ gains complete rights to monalizumab (Anti-NKG2A), also gains option rights to IPH5201 as well as 4 preclinical immuno-oncology molecules
• Innate gains US and EU rights of Lumoxiti approved for HCL in addition to $100m for monalizumab, $50M for IPH5201 (Anti-CD39 mAb) and $20M for 4 preclinical molecules as upfront payment in H1’19 and additional milestones and royalties
• AZ will receive $50M upfront and $25M as milestone along with 9.8% equity in Innate
• The profit sharing of above cross-licensing deal will be done equally b/w the companies. IPH5201 is a CD39 mAb and Lumoxiti is a novel CD22-directed cytotoxin indicated for r/r HCL in the US

Click here to read full press release/ article | Ref: AstraZeneca | Image: Livemint